HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. This event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries. Attendees will have the opportunity t ...

Core Viewpoint - Nexalin Technology, Inc. has successfully enrolled the first patients in a clinical trial for its Deep Intracranial Frequency Stimulation (DIFS™) technology, aiming to treat mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) [1][2][3] Company Overview - Nexalin Technology focuses on developing innovative neurostimulation products to address the global mental health crisis, utilizing non-invasive bioelectronic medical technology [5] - The company's DIFS™ technology is designed to penetrate deep brain structures associated with mental health disorders, potentially offering enhanced patient responses without adverse side effects [5] Clinical Trial Details - The clinical trial is being conducted in collaboration with the University of California, San Diego (UCSD) and the VA San Diego Healthcare System, marking a significant step in evaluating the efficacy of Nexalin's HALO™ Clarity devices [2][3] - The trial aims to gather comprehensive data on the impact of DIFS™ technology on mental health conditions, particularly for underserved populations such as veterans [3][4] Technology and Devices - The HALO™ Clarity device is currently under evaluation and is not yet approved for marketing in the U.S., with its safety and efficacy still being assessed by the FDA [6] - Nexalin's HALO™ Clarity devices provide non-invasive, at-home neurostimulation therapy, integrated with AI for remote monitoring of patient adherence and treatment progress [4]